FDA/EUA Authorized for point-of-care testing
Detect SARS-CoV-2 Virus
95% Relative Sensitivity
Antigen test is based on lateral-flow
immunochromatographic assay and
does not require additional equipment
for detection or analyses. The test
detects antigens specific to SARS-CoV-2
in nasopharyngeal specimens collected
from individuals suspected of being
infected with COVID-19 or exposed
COVID-19 Antibody Rapid Test
is a lateral flow in-vitro
immunoassay intended to detect the
presence of SARS-CoV-2 IgM and IgG antibodies
from a whole blood sample (usually finger prick).
These antibodies develop in our body
in response to a previous
infection by SARS-CoV-2
or in response to vaccination.
Accula Rapid test kit is FDA approved
SARS-Cov-2 test using polymerase chain
reaction (PCR) and lateral flow technologies.
Accula is a molecular in vitro diagnostic
test for the qualitative and visual detection
of nucleic acid from SARS-CoV-2 virus.
Samples are either in nasal or nasal
mid-turbinate swab specimens or
self-collected on site nasal swabs.